A Phase I Dose Escalation Study of SGN-35 Alone and in Combination With Gemcitabine in Patients With Relapsed/Refractory CD30-Positive Hematologic Malignancies.

Trial Profile

A Phase I Dose Escalation Study of SGN-35 Alone and in Combination With Gemcitabine in Patients With Relapsed/Refractory CD30-Positive Hematologic Malignancies.

Discontinued
Phase of Trial: Phase I

Latest Information Update: 01 Jan 2015

At a glance

  • Drugs Brentuximab vedotin (Primary) ; Gemcitabine
  • Indications Haematological malignancies; Hodgkin's disease
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Seattle Genetics
  • Most Recent Events

    • 12 Jun 2011 Retrospective analysis of two phase I trials, including this trial, presented at the16th Congress of the European Haematology Association (EHA-2011).
    • 05 May 2010 Actual end date (Apr 2010) and actual number of patients (44) added as reported by ClinicalTrials.gov.
    • 05 May 2010 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top